PARTNER 2: Valve-In-Valve TAVR for Failed TAVR in High-Risk Patients Shows Acceptable 5-Year Outcomes
For high-risk patients, valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) for the treatment of failed TAVR with balloon-expandable valves resulted in acceptable outcomes at 5 years according to results from the PARTNER 2 study presented Saturday at the TCT Connect virtual conference.